{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DLBCL&page=7", "query": { "condition": "DLBCL", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 325, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DLBCL&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DLBCL&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T08:32:36.178Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04572763", "title": "Copanlisib Plus Venetoclax in R/R DLBCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Relapsed Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-09-08", "completion_date": "2026-07-29", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 3, "location_summary": "Duarte, California • Boston, Massachusetts • St Louis, Missouri", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572763" }, { "nct_id": "NCT04824092", "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tafasitamab placebo", "type": "DRUG" }, { "name": "Lenalidomide placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 899, "start_date": "2021-05-11", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 47, "location_summary": "Daphne, Alabama • Anaheim, California • Clovis, California + 44 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Harbor City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04824092" }, { "nct_id": "NCT02440685", "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Mantle-Cell", "Lymphoma, Follicular", "Cancer", "Neoplasm", "Tumor", "Lymphoma, Malignant", "Lymphoma, B-cell", "Lymphoma, Non-Hodgkin", "B-Cell Chronic Lymphocytic Leukemia", "B-Cell Leukemia, Chronic", "B-Lymphocytic Leukemia, Chronic", "Chronic Lymphocytic Leukemia", "Leukemia, Lymphocytic, Chronic", "Leukemia, Lymphocytic, Chronic, B Cell", "Myelofibrosis", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "Lymphoma, T Cell, Peripheral", "Peripheral T-Cell Lymphoma", "T-Cell Lymphoma, Peripheral" ], "interventions": [ { "name": "ASN002 Dose Escalation", "type": "DRUG" }, { "name": "ASN002 RD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2015-05", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 12, "location_summary": "Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02440685" }, { "nct_id": "NCT00972478", "title": "Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ann Arbor Stage II Non-Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2010-11-15", "completion_date": "2027-03-06", "has_results": true, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 190, "location_summary": "Mobile, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 132 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00972478" }, { "nct_id": "NCT01829958", "title": "Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non Hodgkin Lymphoma (NHL)", "Diffuse Large B-cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "Geriatric Assessment", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 201, "start_date": "2013-04", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01829958" }, { "nct_id": "NCT05176691", "title": "HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL/SLL", "NHL", "MCL", "MZL", "Lymphoplasmacytic Lymphoma", "Waldenstrom Macroglobulinemia", "Follicular Lymphoma", "DLBCL", "Richter Syndrome" ], "interventions": [ { "name": "HMPL-760", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-02-15", "completion_date": "2022-11-16", "has_results": false, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 12, "location_summary": "Anaheim, California • Atlanta, Georgia • New Orleans, Louisiana + 9 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176691" }, { "nct_id": "NCT04855253", "title": "Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "DLBCL", "Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "DLBCL Arising From Follicular Lymphoma" ], "interventions": [ { "name": "E7777", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tisagenlecleucel", "type": "DRUG" }, { "name": "Axicabtagene Ciloleucel", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel Intravenous Suspension", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-06-09", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04855253" }, { "nct_id": "NCT03106428", "title": "A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Multiple Myeloma", "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "MEDI7247", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 67, "start_date": "2017-03-29", "completion_date": "2020-01-03", "has_results": false, "last_update_posted_date": "2020-02-28", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 10, "location_summary": "Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03106428" }, { "nct_id": "NCT05512390", "title": "A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Follicular Lymphoma" ], "interventions": [ { "name": "ABBV-319", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2023-04-26", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 8, "location_summary": "Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05512390" }, { "nct_id": "NCT03628612", "title": "Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy", "Multiple Myeloma", "DLBCL", "ALL, Adult and Pediatric", "T Cell Lymphoma" ], "interventions": [ { "name": "AUTO CAR T cell therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Autolus Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 500, "start_date": "2018-08-02", "completion_date": "2043-12", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-22T08:32:36.178Z", "location_count": 3, "location_summary": "Miami, Florida • St Louis, Missouri • Austin, Texas", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03628612" } ] }